Efficacy of Implantable Defibrillator Therapy After a Myocardial Infarction

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It plans to enroll 700 participants.

Also called NCT00673842

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 700 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT00673842
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Belgium, Canada, Finland, France, Germany, Hungary, Italy, Norway, Saudi Arabia, Slovakia, South Africa, Spain, Sweden, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT00673842. Randomized; no masking; primary purpose treatment. Start 2011-04-18 (actual); primary completion 2024-10-31 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy of Implantable Defibrillator Therapy After a Myocardial Infarction
Acronym
REFINE-ICD
Condition
Sudden Death
Intervention (Device)
Implantable Cardioverter Defibrillator + Usual Care
Intervention (Other)
Usual care
Lead sponsor
University of Calgary (class: other)
Collaborator
Canadian Institutes of Health Research (CIHR) (class: other government)
Collaborator
Alberta Innovation and Science (class: other)
Collaborator
Medtronic (class: industry)
Collaborator
GE Healthcare (class: industry)
Collaborator
Cardiac Arrhythmia Network of Canada (class: other)
Collaborator
Accelerating Clinical Trials Consortium (class: other)

Record details

Record id
cardio:ct-nct00673842
Content hash
9dd8735b15f2a3feb2a1c6b798a107f3aa4ea7f7ced21c86a6f7f7827e736493